Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Continuous Beta-Lactam Prophylaxis in Lower GI Surgery
jRCTs061230082Active, not recruiting
- Start
- Feb 2024
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of meropenem, piperacillin + tazobactam, ceftolozane + tazobactam, cefepime and metronidazole in surgical site infection (SSI) (4 arms). Primary endpoints: Pharmacokinetic parameters of each drug in plasma, Pharmacokinetic parameters of each drug in peritoneal fluid and 1 more. Started Feb 2024; status: active, not recruiting.
02
Drugs
meropenempiperacillin + tazobactamceftolozane + tazobactamcefepimemetronidazole
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on jRCTs061230082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061230082.